2024

1. A Signal-Finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration–Resistant Prostate Cancer: Results from CYCLONE 1

   Clinical Cancer Research, Vol. 30, Núm. 11, pp. 2377-2383

2. A Validated Highly Sensitive Microsatellite Instability Assay Accurately Identifies Individuals Harboring Biallelic Germline PMS2 Pathogenic Variants in Constitutional Mismatch Repair Deficiency

   Clinical chemistry, Vol. 70, Núm. 5, pp. 737-746

3. A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma

   Journal of Neuro-Oncology, Vol. 166, Núm. 3, pp. 407-415

4. Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial

   Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 42, Núm. 2, pp. 192-204

5. Cell-cycle inhibition and immune microenvironment in breast cancer treated with ribociclib and letrozole or chemotherapy

   npj Breast Cancer, Vol. 10, Núm. 1

6. Correction to: A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma (Journal of Neuro-Oncology, (2024), 166, 3, (407-415), 10.1007/s11060-023-04513-1)

   Journal of Neuro-Oncology

7. Correction: SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022) (Clinical and Translational Oncology, (2023), 25, 9, (2647-2664), 10.1007/s12094-023-03215-4)

   Clinical and Translational Oncology

8. Correction: Update on the management of elderly patients with colorectal cancer (Clinical and Translational Oncology, (2023), 26, 1, (69-84), 10.1007/s12094-023-03243-0)

   Clinical and Translational Oncology

9. Difficulties on the access to innovative targeted therapies for lung cancer in Spain

   Clinical and Translational Oncology, Vol. 26, Núm. 3, pp. 597-612

10. Exploratory analyses of treatment subgroup interaction by PD-L1 status and according to PD-L1 expression in the JAVELIN Bladder 100 trial

    Clinical and Translational Oncology, Vol. 26, Núm. 6, pp. 1532-1538

11. Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma

    Blood, Vol. 143, Núm. 7, pp. 597-603

12. Preventing alpelisib-related hyperglycaemia in HR+/HER2−/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial

    eClinicalMedicine, Vol. 71

13. Pseudomonas aeruginosa Bloodstream Infections Presenting with Septic Shock in Neutropenic Cancer Patients: Impact of Empirical Antibiotic Therapy

    Microorganisms, Vol. 12, Núm. 4

14. RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults with Relapsed Small Cell Lung Cancer

    Journal of Clinical Oncology, Vol. 42, Núm. 19, pp. 2317-2326

15. RET Fusion Testing in Patients With NSCLC: The RETING Study

    JTO Clinical and Research Reports, Vol. 5, Núm. 4

16. Real-world study on microsatellite instability and mismatch repair deficiency testing patterns among patients with metastatic colorectal cancer in Spain

    Clinical and Translational Oncology, Vol. 26, Núm. 4, pp. 864-871

17. SEOM-GEMCAD-TTD clinical guidelines for the management of hepatocarcinoma patients (2023)

    Clinical and Translational Oncology

18. Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, non-randomized, multicenter GEM-SELIBORDARA study

    Haematologica, Vol. 109, Núm. 7, pp. 2219-2228

19. The role of sex and gender in the diagnosis and treatment of lung cancer: the 6th ICAPEM Annual Symposium

    Clinical and Translational Oncology, Vol. 26, Núm. 2, pp. 352-362

20. Update on the management of elderly patients with colorectal cancer

    Clinical and Translational Oncology, Vol. 26, Núm. 1, pp. 69-84